PROSULTIAMINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H24N4O2S2
Molecular Weight	356.507
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCSS\C(CCO)=C(/C)N(CC1=C(N)N=C(C)N=C1)C=O

InChI

InChIKey=UDCIYVVYDCXLSX-SDNWHVSQSA-N

InChI=1S/C15H24N4O2S2/c1-4-7-22-23-14(5-6-20)11(2)19(10-21)9-13-8-17-12(3)18-15(13)16/h8,10,20H,4-7,9H2,1-3H3,(H2,16,17,18)/b14-11+

HIDE SMILES / InChI

Molecular Formula	C15H24N4O2S2
Molecular Weight	356.507
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.drugs.com/international/prosultiamine.html | https://www.ncbi.nlm.nih.gov/pubmed/23945332

Prosultiamine (Alinamin®), a well-known thiamine derivative, was first developed by Takeda Pharmaceutical Company in Japan in the 1950s. The drug is a homolog of allithiamine produced by thiol-type vitamin B1 and allicin. Prosultiamine is converted to vitamin B1 after absorption from the gut. The drug thus enables a long-lasting high blood concentration of vitamin B1, resulting in efficient access of vitamin B1 to nervous tissue. Prosultiamine has cured many patients with vitamin B1 deficiency resulting in beriberi neuropathy and Wernicke’s encephalopathy. Prosultiamine is also a potential treatment for HTLV, since it has been shown to reduce viral load and symptoms.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Apoptosis 155 Target ID: map04210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19578238	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Vitamin B deficiency 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23945332	Primary		Approved 8429	Alinamin Approved Use Vitamin b deficiency
HTLV-associated myelopathy 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23945290 https://www.ncbi.nlm.nih.gov/pubmed/19578238	Primary		Phase I 428	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Disulfide-mediated apoptosis of human T-lymphotrophc virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.	2009	19578238
Therapeutic benefits of an oral vitamin B1 derivative for human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).	2013 Aug 15	23945332

Patents

Sample Use Guides

In Vivo Use Guide

Oral administration of prosultiamine at dosages of 300mg daily for 12 weeks

Route of Administration: Oral

In Vitro Use Guide

Prosultiamine (5uM) in vitro treatment against peripheral blood CD4(+) T-cells of HAM/TSP patients induced a significant decrease of HTLV-I proviral copy numbers by apoptosis of HTLV-I-infected cells

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:34:53 GMT 2023` Edited by `admin` on `Fri Dec 15 15:34:53 GMT 2023`
Record UNII	UI32MM3XE3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PROSULTIAMINE

Official Name

English

TAKETRON

Brand Name

English

BINOVA

Brand Name

English

prosultiamine [INN]

Common Name

English

THIAMINE PROPYL DISULPHIDE

Common Name

English

PROSULTIAMINE [MI]

Common Name

English

Prosultiamine [WHO-DD]

Common Name

English

THIOBETA

Brand Name

English

ALINAMIN

Brand Name

English

THIAMINE PROPYL DISULFIDE

Common Name

English

N-((4-AMINO-2-METHYLPYRIMIDIN-5-YL)METHYL)-N-((1E)-4-HYDROXY-1-METHYL-2-(PROPYLDISULFANYL)BUT-1-EN-1-YL)FORMAMIDE

Systematic Name

English

PROSULTIAMINE [JAN]

Common Name

English

N-((4-AMINO-2-METHYL-5-PYRIMIDINYL)METHYL)-N-(4-HYDROXY-1-METHYL-2-(PROPYLDITHIO)-1-BUTENYL)FORMAMIDE

Systematic Name

English

PROSULTIAMINE [MART.]

Common Name

English

NSC-23893

Code

English

JUBEDEL

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C45812